Entity

Time filter

Source Type

Piscataway, NJ, United States

Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2012-05-22

Oligonucleotides directed against the hypoxia-inducible factor-1 (HIF-1) gene are provided for modulating the expression of HIF-1. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1. Methods of using these compounds for modulation of HIF-1 expression and for the treatment of diseases associated with the hypoxia-inducible factor-1 are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2011-07-14

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2012-12-21

Oligonucleotides directed against the hypoxia-inducible factor-1 (HIF-1) gene are provided for modulating the expression of HIF-1. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1. Methods of using these compounds for modulation of HIF-1 expression and for the treatment of diseases associated with the hypoxia-inducible factor-1 are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2011-09-14

The invention relates to oligomer compounds (oligomers), which target beta-catening mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2013-04-30

The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.

Discover hidden collaborations